Etoposide salvage therapy for refractory germ cell tumors: an update.
Etoposide salvage therapy for refractory germ cell tumors: an update.
复制标题
依托泊苷挽救治疗难治性生殖细胞肿瘤：最新进展。
DOI：
10.1016/s0305-7372(82)80081-9
复制
发表时间：
1982
影响因子：
11.8
通讯作者：
Einhorn,LH
中科院分区：
文献类型：
--
作者：
Williams,SD;Einhorn,LH
引言”在过去的十年里，睾丸生殖细胞肿瘤的治疗取得了巨大的进展。实际上，几乎所有早期疾病患者（6）和约60-70%的播散性疾病患者（2）都可以通过现代疗法治愈。然而，仍有相当比例的转移性疾病患者无法治愈。1978年以前，在印第安纳州大学，用顺铂+长春碱+博莱霉素：：i：阿霉素（PVB±A）治疗4个疗程未能达到完全缓解的患者或完全缓解后复发的患者采用各种含顺铂的方案进行治疗。虽然大多数人获得了进一步的客观反应，但没有治愈。与此同时，我们观察了一小群既往长春碱+博莱霉素治疗失败的患者。顺铂+阿霉素治疗（3）。客观反应频繁，但没有患者经历长期无病生存。大约在这个时候，依托泊苷在生殖细胞肿瘤中的单药活性得到了认可。该药物的当前单药数据见表1。在我们
Introduction"/'he dramatic advances made in the management of testis germ cell tumors in the last decade are well known. Quite realistically, virtually all patients with early stage disease (6) and about 60-70% of patients with disseminated disease (2) can be cured by modern therapy. However, there remains a significant proportion of patients with metastatic disease who fail to be cured. Thus, investigations of secondary treatment regimens are appropriate.Prior to 1978 at Indiana University, patients who failed to attain complete remission with 4 courses of c/s-platinum+ vinblastine+ bleomycin:: i: adriamycin (PVB±A) or those who relapsed from complete remission were treated with a variety of secondary c/splatinum-containing regimens. Although most attained a further objective response, there were no cures. At the same time, we saw a small group of patients who had failed prior vinblastine+ bleomycin. They were treated with cis-platinum+ adriamycin (3). Objective responses were frequent, but no patient experienced long disease-free survival. At about this time, the single-agent activity of etoposide in germ cell tumors was recognized. Current single-agent data for this drug are shown in Table 1. In our